Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Rheumatoid Arthritis

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Rheumatoid Arthritis

5 stories · every one Fact-Checked
Zemprocitinib maintains clinical response through week 76 in the Phase III COURAGE-RA rheumatoid arthritis trial.Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid ArthritisLynk Pharmaceuticals reports sustained zemprocitinib responses through week 76 in Phase III COURAGE-RA, with efficacy and long-term safety limitations. Written…28 Oct 2026 · 4 min read
Fact-Checked
Forward Therapeutics FT2109 Phase 1 study oral TNFR1 signaling inhibitorHealth TidingsForward Reports Positive Phase 1 Data for FT2109, Advances to Phase 2 in Rheumatoid ArthritisForward Therapeutics reported favorable Phase 1 safety, tolerability and pharmacokinetic findings for oral TNFR1 signaling inhibitor FT2109 in healthy participants, supporting advancement into Phase 2 development.6 Oct 2026 · 3 min read
Fact-Checked
Resomelagon 40 mg shows stronger ACR20 response in treatment-naïve rheumatoid arthritis patients in SynAct Pharma’s Phase 2b ADVANCE analysisClinical TrialsResomelagon Shows Clearer Efficacy Signal in Post-Hoc Rheumatoid Arthritis AnalysisSynAct Pharma’s post-hoc Phase 2b ADVANCE analysis found that resomelagon 40 mg plus methotrexate produced a stronger ACR20 response than placebo plus methotrexate in treatment-naïve patients with highly…8 Sep 2026 · 4 min read
Fact-Checked
Spyre Therapeutics SPY072 Phase 2 SKYWAY trial rheumatoid arthritis resultsClinical TrialsSpyre’s SPY072 Shows Efficacy Signals in Rheumatoid Arthritis, but Falls Short of Monotherapy BarSpyre Therapeutics’ SPY072 demonstrated proof-of-mechanism and statistically significant benefits on selected endpoints in the Phase 2 SKYWAY-RA trial, but the treatment effect did not meet the company’s threshold…27 Aug 2026 · 3 min read
Fact-Checked
A scientist in protective clothing uses a microscope for research in a laboratory setting.Mergers & AcquisitionsChemomab, Scipher Merge to Advance Nebokitug in Rheumatoid ArthritisChemomab Therapeutics and Scipher Medicine will merge to create Scipher Medicine Corporation, focused on precision medicine in autoimmune disease.8 Jul 2026 · 3 min read
Fact-Checked
Page 1 of 1